Global Varicella Vaccines Market is valued at USD 3.21 Billion in 2021 and expected to reach USD 4.76 Billion by 2028 with a CAGR of 5.8% over the forecast period.
Global Varicella Vaccines Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Increasing prevalence of chickenpox, rising adoption of Varicella vaccines and growing number of research and development activities in this field are some of the major factors anticipated to drive the growth of Global Varicella Vaccines Market.
A varicella vaccine gives protection against chickenpox. Varicella vaccine is also called as chickenpox vaccine. Varicella-zoster are herpes family which causes chickenpox. Chickenpox is highly infectious common in childhood. Adult chickenpox is rare but if happens it may be more severe. The person recovered from chickenpox carry the virus in inactive form in their body for years and herpes zoster (shingles) occurs when the virus becomes active again. Chickenpox causes high grade fever and rashes all over the body. Varicella vaccine needs 2 doses. The first dose is given in the babies from 12 to 15 months and second dose is given from 4 to 6-year kids. The first live attenuated varicella vaccine was produced in 1970s. The varicella vaccine is 95% effective in preventing the disease but instead of one dose, two doses of vaccine will give lifetime immunity.
The Covid-19 pandemic has shown a negative impact on the growth of global varicella vaccines market. The increasing cases of Covid-19 government-imposed lockdown and due to lockdown, there was decline in routine pediatric vaccine ordering, doses administration and hospital visits. Hence, the Varicella vaccines market was affected during pandemic.
The global varicella vaccines market is segmented into on the basis of vaccine type, application, provider and region & country level. On the basis of vaccine type, the global Varicella vaccines market is classified into monovalent vaccines and combination vaccine. On the basis of application, the market is classified into chickenpox, herpes zoster, mumps/measles/rubella/varicella (MMRV)] and others. On the basis of provider, the market is classified into public ad private.
The regions covered in global varicella vaccines market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global Varicella vaccines market is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
On June 25th, 2022; BioNTech and Pfizer collaborated to develop an mRNA vaccine to protect against shingles. A recombinant shingles vaccine produced by GlaxoSmithKline already exists called Shingrix. Shingles is the reactivation of the varicella-zoster virus, the identical virus that causes chickenpox and subsequently lives dormant within the body.
On November 24th, 2021; The Shingrix vaccine (two doses) will be given in free of cost to geriatric population in island. The value is being covered by the provincial government. Shingrix may be a two-dose vaccine given within two to 6 months apart for optimal protection against shingles.
One of the major factors driving the growth of the global varicella vaccines market is increasing prevalence of chickenpox. The vaccination is most important for controlling the spread of chickenpox also World Health Organization (WHO) suggested one or two doses of the Varicella vaccine. Thus, increasing number of chickenpox is supplementing the demand of varicella vaccines. For instance; according to Center of Disease Control and Prevention; there were about 80-90 million cases of chickenpox every year. In addition, another major driving the growth of global Varicella vaccines market is rising adoption of Varicella vaccines. The Varicella vaccine proved to be 90% effective for the chickenpox. For instance, according to CDC the vaccine against chickenpox has reduced worldwide cases of chickenpox infection to 400,000 cases per year from over 4,000,000 cases. Thus, this tremendous success led to increase the adoption of varicella vaccines.
Moreover, growing advancements in this field are also augmenting the market growth. For example; as per the news published on May 26th, 2019, SK Bioscience Sky Zoster NBP608 herpes zoster vaccine compared with Zostavax and the zoster vaccine Sky Zoster (NBP608) was found to be non-inferior to Zostavax. This research increases the future growth of the Varicella vaccine market. Furthermore, growing immunization programs of varicella vaccines are also driving the market growth.
However, high-cost for the development of Varicella vaccines may hamper the growth of the global Varicella vaccine market. In spite of that, rising research and development in emerging countries are expected to provide opportunities to the growth of the global Varicella vaccine market.
North America is expected to show significant growth in the global varicella vaccines market due to rising incidences of varicella infections, the presence of key players, and highly developed healthcare infrastructure in this region. For example; as per the Centers for Disease Control and Prevention (CDC); there were 3.5 million cases of chickenpox or Varicella every in the U.S. In addition, the presence of key players also drives the Varicella vaccines market in this region. For instance, as per the news published on July 25th, 2018, U.S. Food and Drug Administration (FDA) permitted Merk’s vaccine that is Varicella Virus Vaccine Live (VARIVAX). Furthermore, the presence of highly developed healthcare infrastructure and growing healthcare spending is also augmenting the growth of varicella vaccines in this region.
Asia Pacific is expected to be the fastest-growing region in the global varicella vaccines market due to growing vaccine industry, and improving healthcare infrastructure in this region. For example; in December 2019, Sinovac Biotech Ltd. reported the sanction from China National Medical Products Administration (NMPA) for its Varicella immunization showed against Varicella-zoster infection for youngsters matured 1 to 12 years of age.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2021:||USD 3.21 Billion|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 4.76 Billion|
|Tables, Charts & Figures:||175|
|Varicella Vaccine Manufacturers||Emergent BioSolutions Inc., CSL Limited, Sanofi, GlaxoSmithKline plc , Merck & Co., Inc., Pfizer Inc., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Company Limited, Johnson & Johnson, AstraZeneca PLC, Biken, Keygen, Green Cross and others.|
|Segments Covered||By Vaccine Type, By Application, By Provider|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|